Panitumumab: A safe option for oncologic patients sensitized to galactose-α-1,3-galactose

J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):982-3. doi: 10.1016/j.jaip.2015.06.015. Epub 2015 Jul 17.

Authors

Patricia Caponetto¹, Tilo Biedermann², Amir S Yazdi³, Jörg Fischer¹

Affiliations

¹ Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
² Department of Dermatology, Eberhard Karls University, Tübingen, Germany; Department of Dermatology and Allergy, Biederstein, Technical University, Munich, Germany.
³ Department of Dermatology, Eberhard Karls University, Tübingen, Germany. Electronic address: amir.yazdi@med.uni-tuebingen.de.

PMID: 26194457
DOI: 10.1016/j.jaip.2015.06.015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Colorectal Neoplasms / drug therapy*
Galactose / immunology*
Humans
Hypersensitivity / immunology*
Immunoglobulin E / immunology
Panitumumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Immunoglobulin E
Panitumumab
Galactose